Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.1414.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 32.92% | 41.25% | 44.88% | 48.35% | 30.30% |
| Total Depreciation and Amortization | -58.82% | -51.18% | -45.09% | -34.73% | -17.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -93.09% | -69.12% | -68.44% | -58.96% | 0.10% |
| Change in Net Operating Assets | 122.64% | -630.19% | 59.03% | 33.00% | 47.14% |
| Cash from Operations | 16.39% | 26.43% | 41.02% | 44.70% | 38.43% |
| Capital Expenditure | -26.67% | 12.63% | 21.37% | 56.36% | 97.33% |
| Sale of Property, Plant, and Equipment | -41.46% | 859.42% | 573.67% | 1,624.06% | 2,397.56% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 31.13% | -47.29% | -52.90% | 126.56% | 125.99% |
| Cash from Investing | 16.05% | -27.35% | -31.90% | 134.89% | 129.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -53.95% | -53.69% | 875.90% | 1,039.65% | 1,037.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -322.22% | -322.22% | -3,641.18% | -322.22% | -- |
| Cash from Financing | -65.15% | -65.45% | 982.51% | 1,692.78% | 1,342.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.16% | -698.03% | 101.24% | 105.10% | 101.49% |